Summary & Overview
HCPCS Level II J7520: Sirolimus, Oral, 1 mg
HCPCS Level II code J7520 designates sirolimus, oral, 1 mg, a systemic immunosuppressive agent commonly used in transplant medicine and certain autoimmune conditions. Nationally, accurate billing of J7520 matters for drug cost tracking, formulary management, and claims adjudication for outpatient dispensing of oral sirolimus.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J7520 is defined, typical sites of service for billing, and the clinical context in which oral sirolimus is used. The publication also summarizes payer coverage patterns, reimbursement benchmarks, and coding considerations that affect billing workflows and pharmacy claims processing.
This summary provides practitioners, coding professionals, and policy analysts with essential reference material: the billing code definition, common billing scenarios, and where to expect variations in coverage and payment. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code J7520 represents sirolimus, oral, 1 mg, a systemic immunosuppressant medication supplied in oral dosage form. This code is used to bill for the drug product itself as administered or dispensed in outpatient and ambulatory settings where oral prescription medications are provided.
-
Service type: Drug administration/dispensing (oral systemic therapy)
-
Typical site of service: Outpatient pharmacy, ambulatory clinic, or other outpatient settings where oral medications are dispensed or provided to patients
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J7520 (Sirolimus, oral, 1 mg) is an adult or pediatric solid-organ transplant recipient (commonly kidney or liver) undergoing long-term immunosuppressive therapy to prevent graft rejection. The clinical workflow begins with transplantation and establishment of an individualized immunosuppressive regimen by the transplant physician (nephrologist, transplant surgeon, or transplant hepatologist). Sirolimus may be initiated post-transplant or transitioned into the maintenance phase when clinicians aim to minimize calcineurin inhibitor exposure due to nephrotoxicity or other adverse effects.
Medication management includes baseline assessment of renal and hepatic function, therapeutic drug monitoring of sirolimus trough levels, review for drug–drug interactions (notably with strong CYP3A4 inhibitors or inducers), and patient counseling on adherence and infection risk. Prescriptions for J7520 are typically processed by the outpatient pharmacy for home oral administration; billing may occur in ambulatory clinic encounters, infusion centers when handled as a clinic-dispensed oral agent, or during hospital outpatient visits. Documentation includes indication, dosing regimen, trough concentrations, adverse effects, and concurrent immunosuppressive medications.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |